Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers
Status:
Recruiting
Trial end date:
2031-04-30
Target enrollment:
Participant gender:
Summary
This phase II trial tests how well neratinib prior to the primary treatment (neoadjuvant)
works in treating patients with stage I-III HER2 mutated lobular breast cancers. Neratinib is
in a class of medications called kinase inhibitors. It works by blocking the action of an
abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of
cancer cells. Giving neratinib in addition to normal therapy may work better in treating
cancer than the endocrine therapy patients would normally receive.
Phase:
Phase 2
Details
Lead Sponsor:
Vanderbilt-Ingram Cancer Center
Collaborators:
National Cancer Institute (NCI) Puma Biotechnology, Inc.